ATE414151T1 - Antikörper gegen eotaxin und deren verwendung - Google Patents
Antikörper gegen eotaxin und deren verwendungInfo
- Publication number
- ATE414151T1 ATE414151T1 AT01907990T AT01907990T ATE414151T1 AT E414151 T1 ATE414151 T1 AT E414151T1 AT 01907990 T AT01907990 T AT 01907990T AT 01907990 T AT01907990 T AT 01907990T AT E414151 T1 ATE414151 T1 AT E414151T1
- Authority
- AT
- Austria
- Prior art keywords
- eotaxin
- antibodies
- cat
- specific binding
- binding members
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18724600P | 2000-03-03 | 2000-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE414151T1 true ATE414151T1 (de) | 2008-11-15 |
Family
ID=22688187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01907990T ATE414151T1 (de) | 2000-03-03 | 2001-03-02 | Antikörper gegen eotaxin und deren verwendung |
Country Status (14)
Country | Link |
---|---|
US (6) | US7323311B2 (de) |
EP (1) | EP1259615B1 (de) |
JP (1) | JP5198704B2 (de) |
AT (1) | ATE414151T1 (de) |
AU (1) | AU778392B2 (de) |
BR (1) | BRPI0108923B8 (de) |
CA (1) | CA2401342C (de) |
DE (1) | DE60136527D1 (de) |
GB (1) | GB2361704C (de) |
IL (2) | IL151499A0 (de) |
MX (1) | MXPA02008472A (de) |
NO (1) | NO20024179L (de) |
NZ (1) | NZ521182A (de) |
WO (1) | WO2001066754A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5198704B2 (ja) | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
CN1622958B (zh) | 2001-08-23 | 2013-04-03 | Rsr有限公司 | 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 |
MXPA05010222A (es) * | 2003-03-24 | 2006-05-22 | Mercia Pharma Llc | Metodos y composiciones para tratar y prevenir condiciones inflamatorias. |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
CN101163502A (zh) | 2005-02-08 | 2008-04-16 | 根茨美公司 | 针对TGFβ的抗体 |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
PT1999152E (pt) | 2006-03-27 | 2013-01-07 | Medimmune Ltd | Elemento de ligação para o recetor de gm-csf |
EP3683317A3 (de) | 2009-05-13 | 2020-09-30 | Genzyme Corporation | Anti-human-cd52-immunglobuline |
US8176867B2 (en) | 2009-05-28 | 2012-05-15 | Richard J. A. Gayton | Watercraft immobilizing system |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
KR101919170B1 (ko) | 2010-11-19 | 2018-11-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 중화 항-ccl20 항체 |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US20140271666A1 (en) * | 2013-03-14 | 2014-09-18 | Immune Pharmaceuticals Ltd. | Use of anti-eotaxin antibodies for treating inflammatory bowel disease |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
EP3050574B1 (de) | 2015-01-28 | 2019-10-09 | Universite De Bordeaux | Verwendung von Plerixafor zur Behandlung und/oder Vorbeugung von akuten Exazerbationen einer chronisch obstruktiver Lungenerkrankung |
KR102261618B1 (ko) | 2015-03-31 | 2021-06-04 | 메디뮨 리미티드 | 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법 |
AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
AU2017272804B2 (en) | 2016-06-02 | 2023-11-23 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
WO2017212488A1 (en) * | 2016-06-06 | 2017-12-14 | Hadasit Medical Research Service And Development Ltd. | Anti-eotaxin for immunoprotection and hepatoprotection |
CA3172367A1 (en) | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
ES2199216T3 (es) * | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
IL103758A (en) | 1991-12-13 | 1998-07-15 | Akzo Nv | Cancer-specific monoclonal antibodies |
NZ273052A (en) * | 1993-09-14 | 1997-12-19 | Imperial College | Chemoattractant protein capable of attracting eosinophils and inducing accumulation thereof |
US6403782B1 (en) | 1995-06-22 | 2002-06-11 | President And Fellows Of Harvard College | Nucleic acid encoding eotaxin |
US7265201B1 (en) * | 1995-06-23 | 2007-09-04 | Millennium Pharmaceuticals, Inc. | Human chemotactic cytokine |
WO1997012914A1 (en) | 1995-10-05 | 1997-04-10 | Shionogi & Co., Ltd. | Novel human cc chemokine |
WO1999010534A1 (en) | 1997-08-22 | 1999-03-04 | Center For Blood Research, Inc. | Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof |
GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2690395C (en) * | 1998-06-22 | 2013-11-05 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
EP1212422B1 (de) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
JP5198704B2 (ja) * | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2001
- 2001-03-02 JP JP2001565908A patent/JP5198704B2/ja not_active Expired - Lifetime
- 2001-03-02 CA CA2401342A patent/CA2401342C/en not_active Expired - Lifetime
- 2001-03-02 WO PCT/GB2001/000927 patent/WO2001066754A1/en active IP Right Grant
- 2001-03-02 US US10/220,418 patent/US7323311B2/en not_active Expired - Lifetime
- 2001-03-02 MX MXPA02008472A patent/MXPA02008472A/es unknown
- 2001-03-02 DE DE60136527T patent/DE60136527D1/de not_active Expired - Lifetime
- 2001-03-02 AT AT01907990T patent/ATE414151T1/de not_active IP Right Cessation
- 2001-03-02 BR BR0108923A patent/BRPI0108923B8/pt not_active IP Right Cessation
- 2001-03-02 GB GB0105237A patent/GB2361704C/en not_active Expired - Lifetime
- 2001-03-02 IL IL15149901A patent/IL151499A0/xx unknown
- 2001-03-02 EP EP01907990A patent/EP1259615B1/de not_active Expired - Lifetime
- 2001-03-02 NZ NZ521182A patent/NZ521182A/en not_active IP Right Cessation
- 2001-03-02 AU AU35852/01A patent/AU778392B2/en not_active Expired
-
2002
- 2002-08-27 IL IL151499A patent/IL151499A/en active IP Right Grant
- 2002-09-02 NO NO20024179A patent/NO20024179L/no not_active Application Discontinuation
-
2007
- 2007-12-17 US US11/958,210 patent/US8067564B2/en not_active Expired - Fee Related
-
2011
- 2011-10-19 US US13/277,132 patent/US8715961B2/en not_active Expired - Lifetime
-
2014
- 2014-03-24 US US14/223,561 patent/US9284589B2/en not_active Expired - Fee Related
-
2016
- 2016-02-03 US US15/014,945 patent/US10577413B2/en not_active Expired - Fee Related
-
2020
- 2020-09-03 US US17/011,379 patent/US20210277103A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414151T1 (de) | Antikörper gegen eotaxin und deren verwendung | |
LU93274I2 (fr) | Elotuzumab | |
ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
LTPA2017043I1 (lt) | Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas | |
DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
PT1299421E (pt) | Anticorpos para a mcp-1 humana | |
DE60031279D1 (de) | Humane monoklonale antikörper gegen prostata spezifisches membranantigen | |
DE60040301D1 (de) | Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung | |
ATE435239T1 (de) | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen | |
DK3284753T3 (da) | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose | |
ATE251942T1 (de) | Stapelbare statische mischelemente | |
WO2004043989A3 (en) | Human monoclonal antibodies to heparanase | |
DK1265928T3 (da) | RSV-neutraliserende antistoffer med ultra høj affinitet | |
NO984136D0 (no) | Humanisert kimært antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl | |
DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
DE602004031635D1 (de) | Tumorvaskulatur zielrichtung mittels verwendung eines gegen fibronectin ed-b radiomarkierten antikörpers l19 | |
SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer | |
ATE372349T1 (de) | Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen | |
TH64455A (th) | สารภูมิต้านทาน mcp-1 ในมนุษย์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |